Extended Migraine Prophylactics Market Size, Share and Trends 2025 to 2034

Revenue, 2024

USD 3.61 Bn

Forecast Year, 2034

USD 11.66 Bn

CAGR, 2025 - 2034

12.44%

Report Coverage

Global

What is the Extended Migraine Prophylactics Market Size?

The global extended migraine prophylactics market size is calculated at USD 4.06 billion in 2025 and is predicted to increase from USD 4.56 billion in 2026 to approximately USD 11.66 billion by 2034, expanding at a CAGR of 12.44% from 2025 to 2034. This market is growing due to the rising prevalence of chronic migraines and increasing adoption of long-acting preventive therapies that offer improved patient compliance and sustained symptom relief.

Market Highlights

• North America dominated the market, holding the largest market share of 40% in 2024.
• The Asia Pacific is expected to expand at the fastest CAGR of 30% between 2025 and 2034.
• By product type, the oral tablets & capsules segment contributed the major market share of 55% in 2024.
• By product type, the injectables/biologics segment is expected to grow at a remarkable CAGR of 20% between 2025 and 2034.
• By mechanism of action, the calcitonin gene-related peptide (CGRP) inhibitor segment captured the highest market share of 40% in 2024.
• By mechanism of action, the beta-blockers segment is growing at a strong CAGR of 25% between 2025 and 2034.
• By route of administration, the oral segment accounted for the largest share of 65% in 2024.
• By route of administration, the injectable segment is expanding at a strong CAGR of 20% between 2025 and 2034.
• By treatment type, the preventive/prophylactic therapy segment held the major market share of 60% in 2024.
• By treatment type, the acute/rescue therapy segment is growing at a solid CAGR between 2025 and 2034.
• By distribution channel, the retail pharmacies segment generated the highest market share of 66.50% in 2024.
• By distribution channel, the online pharmacies/e-commerce segment is expanding at a strong CAGR of 15% between 2025 and 2034.

What is Extended Migraine Prophylactics?

The extended migraine prophylactics market is witnessing strong growth, driven by the growing number of migraine sufferers and the growing use of long-acting preventive medications that enhance treatment adherence. In addition, new CGRP-based treatments growing approvals across age groups and increased awareness of migraine management are driving up market demand.

Case Study: In August 2025, Teva Pharmaceuticals received FDA approval expanding AJOVY use for pediatric migraine prevention.

Extended Migraine Prophylactics Market Outlook

[[market_outlook]]

Market Scope

Biopharma's Next Horizon: Cell and Gene Therapies Transforming Chronic Disease Management

Extended Migraine Prophylactics Market Segmental Insights

[[segment_insights]]

Extended Migraine Prophylactics MarketRegional Insights

[[regional_insights]]

Extended Migraine Prophylactics Market Value Chain

[[value_chain]]

Extended Migraine Prophylactics Market Companies

[[market_company]]

Other Players in the Market

• Eli Lilly Eli Lilly is a leading research-based pharmaceutical company that develops biologics and small-molecule therapies for neurological disorders, including migraine prevention. Its product Emgality (galcanezumab) is a calcitonin gene-related peptide (CGRP) monoclonal antibody approved for migraine prophylaxis and cluster headache management, positioning Lilly as a major player in the preventive migraine market.
• Novartis : Novartis offers Aimovig (erenumab), one of the first CGRP receptor antagonists for migraine prevention, co-developed with Amgen. The company leverages advanced R&D and digital health tools to expand its neuroscience portfolio, focusing on improving treatment adherence and outcomes in chronic migraine patients.
• Teva Pharmaceuticals : Teva provides Ajovy (fremanezumab), a long-acting monoclonal antibody targeting CGRP for preventive migraine treatment. Its focus on dosing flexibility and accessibility, combined with its global distribution network, makes Teva a key competitor in migraine prophylaxis.
• Novo Nordisk: Novo Nordisk is expanding its chronic disease expertise into neurology through partnerships and research in neurovascular and metabolic links to migraine. The company long-term focus on hormonal and neurobiological pathways positions it for future innovation in migraine management.
• Pfizer: Pfizer develops and markets therapeutics targeting neurological and pain-related disorders. Following its acquisition of Biohaven Pharmaceuticals, Pfizer gained access to rimegepant (Nurtec ODT) and zavegepant, expanding its presence in both acute and preventive migraine therapies.
• Johnson & Johnson: Johnson & Johnson, through its Janssen Pharmaceuticals division, conducts research in neuroinflammation and pain modulation. Its innovation in biologics and neuroscience is shaping next-generation treatments that may extend to migraine prevention and chronic headache management.
• UCB: UCB specializes in neurological and immunological diseases, focusing on monoclonal antibody and peptide-based therapeutics. The companys expanding neuroscience pipeline includes candidates targeting central sensitization and pain pathways relevant to migraine prophylaxis.
• Merck & Co.: Merck has a history of innovation in pain and neurology, including early migraine research. Its ongoing work in neurobiology and anti-inflammatory therapeutics continues to support the development of advanced migraine prevention solutions.
• Allergan (an AbbVie company): Allergan, now part of AbbVie, remains a major player in migraine prophylaxis with Botox (onabotulinumtoxinA), approved for chronic migraine prevention. AbbVie acquisition of Allergan has strengthened its portfolio with both biologic and small-molecule options targeting multiple migraine pathways.
• Biohaven Pharmaceuticals: Biohaven, acquired by Pfizer, pioneered CGRP receptor antagonists for acute and preventive migraine treatment, including Nurtec ODT (rimegepant) and zavegepant. The company innovative dual-action therapies and patient-centric models have set new standards in migraine care.
• Lundbeck: Lundbeck focuses on neurological and psychiatric diseases, offering migraine prophylactic drugs such as Vyepti (eptinezumab), a CGRP monoclonal antibody administered intravenously. Its neuroscience expertise and patient-oriented innovation make it a major contributor to the migraine prevention landscape.
• Avanir Pharmaceuticals: Avanir, a subsidiary of Otsuka, develops treatments for central nervous system disorders, including migraine and pain syndromes. The company research in neuroinflammation and neurotransmitter regulation supports its pipeline of potential migraine prophylactic therapies.
• Chugai Pharmaceutical: Chugai, part of the Roche Group, develops antibody-based therapeutics and targeted biologics that extend into pain and neurological disorder management. Its focus on molecularly targeted drugs aligns with emerging strategies in migraine prevention.
• Kyowa Kirin: Kyowa Kirin develops and commercializes novel biologics for neurological and immunological disorders. The companys pipeline includes innovative small molecules and antibodies with potential applications in chronic migraine prophylaxis and pain modulation.
• Amneal Pharmaceuticals: Amneal produces generic and specialty pharmaceuticals, including neurology-focused formulations. The company is expanding its presence in migraine and central nervous system therapies, providing affordable access to preventive and acute treatments.
• Dr. Reddy's Laboratories: Dr. Reddy manufactures generic formulations for neurological and pain disorders, contributing to cost-effective migraine management. The company R&D in biosimilars and specialty injectables supports broader access to migraine prophylactic therapies.
• Sun Pharma: Sun Pharmaceutical Industries develops and markets specialty therapeutics across neurology and chronic pain management. The company is investing in migraine-related R&D and distribution partnerships to expand its role in preventive and symptomatic treatment markets.

Extended Migraine Prophylactics MarketSegments Covered in the Report

[[segment_covered]]